Scientists in the US say they have developed an mRNA-based vaccine that encompasses ... way to go from the animal model to humans. The type of response, the extent of the response, the persistence ...

Lastly, vaccine hesitancy could plague vaccine-focused firms like Moderna if new concerns about safety issues begin to emerge from the firm's novel mRNA vaccines. We model this into our demand ...

Moderna MRNA incurred a loss of $2.52 per share in the first quarter of 2025, narrower than the Zacks Consensus Estimate of a ...

Moderna MRNA is expected to report first-quarter 2025 earnings on May 1, before the opening bell. The company’s earnings beat ...

Lawmakers in Iowa, Montana, Idaho, Texas and Kentucky introduced bills that would ban or restrict vaccines that use messenger RNA, or mRNA, technology — despite its immense potential for ...

The identification and intervention of Alzheimer's Disease (AD) in its early-stage allows for the timely implementation of lifestyle modifications and therapeutic strategies. Although dysregulation of ...

In that respect it follows a similar model to Merck's takeover of AmpTec, another CDMO that uses a PCR platform to make mRNA drugs, for an undisclosed sum last year. Outsourcing services are on of ...

In the latest trading session, Moderna (MRNA) closed at $27.19, marking a -0.75% move from the previous day. This change lagged the S&P 500's 0.74% gain on the day. On the other hand, the Dow ...